A decision about the experiment
FLOW randomized 3,533 people with type 2 diabetes and chronic kidney disease to semaglutide or placebo. Median follow-up was 3.4 years. An early end to the trial was recommended after a prespecified interim analysis. This was a decision about accumulating research evidence, not a tested on-and-off schedule.
Read the combined outcome carefully
The primary outcome combined kidney failure, a large decline in kidney function, and kidney-related or cardiovascular death. First events numbered 331 versus 410, with a hazard ratio of 0.76. That relative comparison describes the defined composite; it does not mean every participant experienced a 24% improvement in kidney function.
What a stopping rule cannot answer
A trial’s stopping rule and a patient’s treatment decision operate at different levels. To support cycling, an experiment would need to compare relevant interruption and restart strategies. An early research conclusion cannot fill that missing comparison, and years of follow-up cannot guarantee lifetime safety.
Keep the population and limits visible
These findings concern people with both diabetes and kidney disease. They do not establish a preventive regimen for healthy adults or validate research-vial products. We reviewed the full indexed abstract; the study was funded by Novo Nordisk. This is an explanation of a 2024 trial, newly featured by S7, with conceptual artwork and no personal treatment schedule.